We provide trade advice to complement the prevailing
expert consensus on Edesa Biotech. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. Edesa Biotech dividends can provide a clue to the current value of the stock. The firm is not expected to issue dividends this year as it is trying to preserve or re-invest any of the funds available for distribution to stakeholders.
Typically, a company's
financial statements are the reports that show the
financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Edesa Biotech income statement, its balance sheet, and the statement of cash flows. Potential Edesa Biotech investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Edesa Biotech investors may use each financial statement separately, they are all related. The changes in Edesa Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Edesa Biotech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our
technical analysis and
fundamental analysis pages.
The goal of Edesa Biotech
fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Edesa Biotech performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Edesa Biotech shares is the value that is considered the true value of the share. If
the intrinsic value of Edesa is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Edesa Biotech. Please read more on our
fundamental analysis page.
How effective is Edesa Biotech in utilizing its assets?
Edesa Biotech reports assets on its Balance Sheet. It represents the amount of Edesa resources that either has an existing economic value or will provide some form of benefits in the future. By effectively utilizing its assets, Edesa Biotech aims to generate revenue, control costs, drive operational efficiency, and enhance profitability. Optimizing asset utilization helps maximize shareholder value and maintain a competitive position in the Biotechnology space. To get a better handle on how balance sheet or income statements item affect Edesa volatility, please check the breakdown of all its
fundamentals.
Are Edesa Biotech Earnings Expected to grow?
The
future earnings power of Edesa Biotech involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Edesa Biotech factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Edesa Biotech
stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Edesa
expected earnings.
Edesa Biotech Gross Profit
Edesa Biotech Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Edesa Biotech previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Edesa Biotech Gross Profit growth over the last 10 years. Please check Edesa Biotech's
gross profit and other
fundamental indicators for more details.
Another Deeper Perspective
Although in the United States, the Securities and Exchange Commission has enforced strong rules to prevent insiders from engaging in insider trading, finding insiders among active shareholders of Edesa Biotech is not uncomon. Many companies such as Edesa Biotech have both institutions investors and insiders sharing the ownership. Retail investors typically buy and sell stocks in round lots of 100 shares or more. Other other hand institutional investors are known to buy and sell in block trades of 10,000 shares or more. Let's take a look at how the ownership of Edesa is distributed among investors.
Ownership Allocation
Edesa Biotech retains a total of 9.41 Million outstanding shares. Edesa Biotech retains significant amount of outstanding shares owned by
insiders. An
insider is usually defined as a CEO, other corporate executive, director, or
institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Remember, it does not matter who owns the company or if the company is currently
losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
| Retail Investors28.34% | Insiders46.77% | Institutions24.89% |
| Retail Investors | 28.34 |
| Insiders | 46.77 |
| Institutions | 24.89 |
Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Edesa Biotech has an asset utilization ratio of 11.46 percent. This suggests that the company is making $0.11 for each dollar of assets. An increasing asset utilization means that Edesa Biotech is more efficient with each dollar of assets it utilizes for everyday operations.
| Current Assets | 5.82 Million | 97.93 |
| Assets Non Current | 6,822.33 | 0.11 |
| Goodwill | 116,416 | 1.96 |
Another 3 percent rise for Edesa Biotech
Current downside deviation is at 7.21. As of the 30th of August, Edesa Biotech shows the Mean Deviation of 7.64,
coefficient of variation of 848.94, and Downside Deviation of 7.21. Edesa Biotech
technical analysis allows you to utilize
historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of
historical prices and volume momentum, or the prices will eventually revert. We were able to analyze nineteen
technical drivers for Edesa Biotech, which can be compared to its rivals. Please confirm
Edesa Biotech coefficient of variation,
maximum drawdown,
skewness, as well as the
relationship between the
information ratio and
downside variance to decide if Edesa Biotech is priced favorably, providing market reflects its regular price of 8.15 per share. Given that Edesa Biotech has
jensen alpha of 2.08, we urge you to verify Edesa Biotech's prevailing market performance to make sure the company can sustain itself at a future point.
The Current Takeaway on Edesa Biotech Investment
Whereas some other companies under the biotechnology industry are still a bit expensive, Edesa Biotech may offer a potential longer-term growth to investors. While some investors may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Edesa Biotech.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Edesa Biotech. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com